GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

MXCT · Jun 30, 2026

MAXCYTE, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001104659-26-095971General Corporate
Capex intensity0thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.26% · OPTIONAL · VALID

Operating cash generation92thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-94.43% · OPTIONAL · VALID

Revenue growth25thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

-15.25% · CORE · VALID

Inventory pressure42thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

157.98% · OPTIONAL · VALID

Gross margin8thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

113.37% · CORE · VALID

Operating margin92thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-207.29% · CORE · VALID

R&D intensity8thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

86.16% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

23.50% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building
Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20257/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
1.60%
Current
1.26%
Delta
-0.34%
Cash Generation Increased
Previous
-181.49%
Current
-94.43%
Delta
87.06%
Growth Increased
Previous
-21.63%
Current
-15.25%
Delta
6.38%
Inventory Pressure Decreased
Previous
169.54%
Current
157.98%
Delta
-11.56%
Margin Decreased
Previous
179.56%
Current
113.37%
Delta
-66.19%
Profitability Decreased
Previous
-137.41%
Current
-207.29%
Delta
-69.88%
R And D Intensity Increased
Previous
85.69%
Current
86.16%
Delta
0.47%
Sbc Intensity Decreased
Previous
25.35%
Current
23.50%
Delta
-1.85%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Compared To · Services-Commercial Physical & Biological Research peers →Has State · MAXCYTE, INC. →Transitioned To · MXCT Fundamental State →Transitioned To · MXCT CAPEX_INTENSITY_DECREASED →Transitioned To · MXCT CASH_GENERATION_INCREASED →Transitioned To · MXCT GROWTH_INCREASED →Transitioned To · MXCT INVENTORY_PRESSURE_DECREASED →Transitioned To · MXCT MARGIN_DECREASED →Transitioned To · MXCT PROFITABILITY_DECREASED →Transitioned To · MXCT R_AND_D_INTENSITY_INCREASED →Transitioned To · MXCT SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.